183 related articles for article (PubMed ID: 7930220)
1. 26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse.
Maron BJ; Isner JM; McKenna WJ
J Am Coll Cardiol; 1994 Oct; 24(4):880-5. PubMed ID: 7930220
[No Abstract] [Full Text] [Related]
2. 26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse.
Maron BJ; Isner JM; McKenna WJ
Med Sci Sports Exerc; 1994 Oct; 26(10 Suppl):S261-7. PubMed ID: 7934749
[No Abstract] [Full Text] [Related]
3. Cardiovascular abnormalities in the athlete: recommendations regarding eligibility for competition. Task force III: Hypertrophic cardiomyopathy, other myopericardial diseases and mitral valve prolapse.
Maron BJ; Gaffney FA; Jeresaty RM; McKenna WJ; Miller WW
J Am Coll Cardiol; 1985 Dec; 6(6):1215-7. PubMed ID: 4067096
[No Abstract] [Full Text] [Related]
4. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Association and American College of Cardiology.
Maron BJ; Udelson JE; Bonow RO; Nishimura RA; Ackerman MJ; Estes NA; Cooper LT; Link MS; Maron MS;
Circulation; 2015 Dec; 132(22):e273-80. PubMed ID: 26621644
[No Abstract] [Full Text] [Related]
5. 26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 2: acquired valvular heart disease.
Cheitlin MD; Douglas PS; Parmley WW
Med Sci Sports Exerc; 1994 Oct; 26(10 Suppl):S254-60. PubMed ID: 7934748
[No Abstract] [Full Text] [Related]
6. 26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 2: acquired valvular heart disease.
Cheitlin MD; Douglas PS; Parmley WW
J Am Coll Cardiol; 1994 Oct; 24(4):874-80. PubMed ID: 7930219
[No Abstract] [Full Text] [Related]
7. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Association and American College of Cardiology.
Maron BJ; Udelson JE; Bonow RO; Nishimura RA; Ackerman MJ; Estes NAM; Cooper LT; Link MS; Maron MS
J Am Coll Cardiol; 2015 Dec; 66(21):2362-2371. PubMed ID: 26542657
[No Abstract] [Full Text] [Related]
8. Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome.
Maron BJ; Ackerman MJ; Nishimura RA; Pyeritz RE; Towbin JA; Udelson JE
J Am Coll Cardiol; 2005 Apr; 45(8):1340-5. PubMed ID: 15837284
[No Abstract] [Full Text] [Related]
9. Recommendations for participation in competitive sport and leisure-time physical activity in individuals with cardiomyopathies, myocarditis and pericarditis.
Pelliccia A; Corrado D; Bjørnstad HH; Panhuyzen-Goedkoop N; Urhausen A; Carre F; Anastasakis A; Vanhees L; Arbustini E; Priori S
Eur J Cardiovasc Prev Rehabil; 2006 Dec; 13(6):876-85. PubMed ID: 17143118
[TBL] [Abstract][Full Text] [Related]
10. 26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 4: systemic hypertension.
Kaplan NM; Deveraux RB; Miller HS
J Am Coll Cardiol; 1994 Oct; 24(4):885-8. PubMed ID: 7930221
[No Abstract] [Full Text] [Related]
11. 26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 4: systemic hypertension.
Kaplan NM; Deveraux RB; Miller HS
Med Sci Sports Exerc; 1994 Oct; 26(10 Suppl):S268-70. PubMed ID: 7934750
[No Abstract] [Full Text] [Related]
12. 26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 1: congenital heart disease.
Graham TP; Bricker JT; James FW; Strong WB
Med Sci Sports Exerc; 1994 Oct; 26(10 Suppl):S246-53. PubMed ID: 7934747
[No Abstract] [Full Text] [Related]
13. 26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 1: congenital heart disease.
Graham TP; Bricker JT; James FW; Strong WB
J Am Coll Cardiol; 1994 Oct; 24(4):867-73. PubMed ID: 7930218
[No Abstract] [Full Text] [Related]
14. 26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 5: coronary artery disease.
Thompson PD; Klocke FJ; Levine BD; Van Camp SP
J Am Coll Cardiol; 1994 Oct; 24(4):888-92. PubMed ID: 7930222
[No Abstract] [Full Text] [Related]
15. 26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 5: coronary artery disease.
Thompson PD; Klocke FJ; Levine BD; Van Camp SP
Med Sci Sports Exerc; 1994 Oct; 26(10 Suppl):S271-5. PubMed ID: 7934751
[No Abstract] [Full Text] [Related]
16. 26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 6: arrhythmias.
Zipes DP; Garson A
Med Sci Sports Exerc; 1994 Oct; 26(10 Suppl):S276-83. PubMed ID: 7523824
[No Abstract] [Full Text] [Related]
17. 26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 6: arrhythmias.
Zipes DP; Garson A
J Am Coll Cardiol; 1994 Oct; 24(4):892-9. PubMed ID: 7523472
[No Abstract] [Full Text] [Related]
18. Pericardial and myocardial disease.
Ward D
Practitioner; 1993 Dec; 237(1533):929-32. PubMed ID: 8108326
[No Abstract] [Full Text] [Related]
19. [Cardiomyopathies of unexplained etiology (the so-called primary cardiomyopathies)].
Loogen F; Kuhn H
Internist (Berl); 1975 Nov; 16(11):540-7. PubMed ID: 127757
[No Abstract] [Full Text] [Related]
20. Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC).
Pelliccia A; Solberg EE; Papadakis M; Adami PE; Biffi A; Caselli S; La Gerche A; Niebauer J; Pressler A; Schmied CM; Serratosa L; Halle M; Van Buuren F; Borjesson M; Carrè F; Panhuyzen-Goedkoop NM; Heidbuchel H; Olivotto I; Corrado D; Sinagra G; Sharma S
Eur Heart J; 2019 Jan; 40(1):19-33. PubMed ID: 30561613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
